Advertisement
Mr. Bedard brings 25 years of experience, successfully directingdevelopment and registration programs in various therapeutic areas, includingcardiovascular, metabolic, dermatology, gastroenterology and immunology. Hemanaged all aspects of a large regulatory department, which included thefollowing functional areas: FDA liaison, dossier planning and development, andGLP/GCP. John also has a great deal of product registration expertise andfour of the development programs became marketed franchises with annual salesin excess of $1 billion.
Advertisement
"We believe John brings a wealth of experience to this role," said NoahBerkowitz, M.D., Ph.D., President and Chief Executive Officer of SynvistaTherapeutics. "His expertise in regulatory affairs and drug development andregistration will be invaluable as our product candidates, ALT-2074 andalagebrium, progress in the clinical and regulatory process."
Mr. Bedard also serves on EpiCept Corporation's Board of Directors.
On April 2, 2006, John joined MannKind Corporation as Senior VicePresident, Worldwide Regulatory Affairs. From 2002 to April, 2006, Mr. Bedardwas a consultant advising pharmaceutical companies on the development,registration and optimization of their products. From 1989 to 2002, he wasExecutive Director and Director of Strategic Planning then became VicePresident for FDA Liaison and Global Strategy at Bristol-Myers Squibb.Previously, from 1985 to 1988, he was Director then Group Director ofRegulatory Affairs at Smith Kline & French Laboratories. From 1981 to 1985,he was Regulatory Associate then Assistant Director of Regulatory Affairs.Mr. Bedard graduated from Rutgers University with a B.A. in Chemistry. Hereceived his M.S. from Saint Joseph's University.
About Synvista Therapeutics
Synvista Therapeutics is a biopharmaceutical company developing smallmolecule drugs to treat and prevent cardiovascular disease and to treatnephropathy in people with diabetes. The Company has identified severalproduct candidates that it believes represent novel approaches to some of thelargest pharmaceutical markets. The Company's portfolio includes orallybioavailable, organoselenium mimics of glutathione peroxidase. Thesecompounds metabolize lipid peroxides and have the potential to limitmyocardial damage subsequent to a myocardial infarction. SynvistaTherapeutics' lead compound for that program, ALT-2074, is in Phase 2 clinicaltrials. The Company also has rights to the use of haptoglobincharacterization. Synvista is developing a clinical diagnostic test that canbe used to identify patients at high risk for cardiovascular complications ofdiabetes and other diseases.
Synvista Therapeutics also is developing alagebrium, a proposed breaker ofAGEs for the treatment of diastolic heart failure. This disease represents arapidly growing market of unmet medical need, particularly common amongdiabetic patients. Alagebrium has demonstrated relevant clinical activity intwo Phase 2 clinical trials in heart failure, as well as in animal models ofheart failure and nephropathy, among others. Alagebrium has been tested inapproximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials,allowing Synvista Therapeutics to assemble a sizeable human safety database.For more information, please visit the Company's website at www.synvista.com.
Any statements contained in this press release that relate to futureplans, events or performance are forward-looking statements that involve risksand uncertainties including, but not limited to, the risks associated with theevents described in this press release, future clinical development ofSynvista Therapeutics' product candidates, and other risks identified i
